Understanding the different ways hypertrophic cardiomyopathy affects patients
Official title: Hypertrophic Cardiomyopathy: Understanding the Heterogeneity of Disease Expression and Outcomes
Funded at Brigham and Women's Hospital · NIH-10903810 · Data updated 2026-11-12
This study is looking into why some people with hypertrophic cardiomyopathy (HCM) have more severe symptoms than others, using genetic and health information to help improve how we diagnose and manage this heart condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2021 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,272,161 |
| NIH project number | 5R01HL155568-04 |
| Project ID | NIH-10903810 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with hypertrophic cardiomyopathy, particularly those with varying degrees of disease severity.
✕Less likely to help
Patients without a diagnosis of hypertrophic cardiomyopathy or those with other unrelated cardiac conditions may not benefit from this research.
What this research studies
This research investigates hypertrophic cardiomyopathy (HCM), a genetic heart condition that causes thickening of the heart muscle. By analyzing data from a large registry of HCM patients, the study aims to uncover the genetic and phenotypic factors that contribute to the varying severity of the disease among individuals. The research employs advanced genetic analysis and clinical assessments to identify why some patients experience severe symptoms while others have mild forms of the disease. This comprehensive approach seeks to improve diagnosis and management strategies for HCM.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for patients with hypertrophic cardiomyopathy, improving their quality of life and health outcomes.
How similar studies have gone: Previous research has shown promising results in understanding genetic heart disorders, suggesting that this approach could yield valuable insights into hypertrophic cardiomyopathy as well.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Ho, Carolyn Y — Brigham and Women's Hospital
- Study coordinator: Ho, Carolyn Y
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.